Bausch + Lomb Corporation

Equities

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-05-24 pm EDT			5-day change	1st Jan Change
15.02 ^USD	+2.11%		+2.53%	-11.96%

May. 06	Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	MT
May. 06	Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	MT

Bausch + Lomb Corporation Provides Earnings Guidance for the Full Year 2022

June 08, 2022 at 06:59 am EDT

Bausch + Lomb Corporation provided earnings guidance for the full year 2022. For the full year, the company expects revenue range of $3.75 billion – $3.80 billion, reflecting anticipated 4-5% organic growth.

Latest news about Bausch + Lomb Corporation

Bausch + Lomb Shares Rise After Morgan Stanley Upgrade	May. 06	MT
Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16	May. 06	MT
RBC Capital Reviews Bausch + Lomb's Q1 Results	May. 02	MT
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating	May. 02	MT
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	May. 01	MT
Bausch + Lomb Q1 Loss Widens, Revenue Increases	May. 01	MT
Transcript : Bausch + Lomb Corporation, Q1 2024 Earnings Call, May 01, 2024	May. 01
Bausch + Lomb Q1 Net Loss Widens, But Revenue Higher; Raises 2024 Revenue Growth Guidance	May. 01	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	May. 01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	May. 01	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	May. 01	MT
Bausch + Lomb Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Bausch + Lomb Says Study Shows Improvements in Dry Eyes With Nutritional Supplement	Apr. 25	MT
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	CI
RBC Previews Bausch Health's Q1, Trims Target to US$11	Apr. 23	MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	Apr. 22	MT
Bausch + Lomb Q1 Results Likely to be Impacted by Foreign Exchange Headwinds, RBC Says	Apr. 22	MT
RBC Cuts Price Target on Bausch + Lomb to $18 From $20, Keeps Outperform Rating	Apr. 22	MT
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	Apr. 12	MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	Apr. 05	MT
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting	Mar. 27	MT
Bausch + Lomb Brief: Says Will Present New Scientific Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting	Mar. 27	MT

Chart Bausch + Lomb Corporation

Duration

Period

More charts

Company Profile

Bausch + Lomb Corporation is a Canada-based global eye health company. The Companyâs Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Companyâs Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Companyâs brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Bausch + Lomb Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.02 USD

Average target price

18.71 USD

Spread / Average Target

+24.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BAUSCH + LOMB CORPORATION	-11.96%	5.28B
ABBOTT LABORATORIES	-5.56%	181B
MEDTRONIC PLC	-0.11%	108B
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B
DEXCOM, INC.	+2.64%	50.65B
CENCORA, INC.	+6.58%	43.11B
HOYA CORPORATION	+3.40%	41.3B
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B
TERUMO CORPORATION	+16.81%	25.03B
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B

Other Medical Equipment, Supplies & Distribution